A Preview of the Dangerous Future of Abortion Bans — Texas Senate Bill 8
By Whitney Arey, Ph.D et al.,,
The New England Journal of Medicine
| 06. 22. 2022
Photo by Gayatri Malhotra on Unsplash
When the U.S. Supreme Court issues its decision in Dobbs v. Jackson Women’s Health Organization, the abortion care landscape will most likely be changed for at least a generation. Even before a draft opinion was leaked, many experts anticipated that the Court would overturn Roe v. Wade, and nearly half the states are poised to ban or dramatically limit abortion care when that occurs.1 These state laws criminalizing abortion may allow for very narrow exemptions, and anyone who violates the law could be subject to civil penalties, criminal fines, or imprisonment.2
Health systems and clinicians planning their responses3 can look to Texas, where we have already witnessed the impact of strict abortion bans on the provision of evidence-based, essential health care for pregnant people. Since September 1, 2021, Texas Senate Bill 8 (SB8) has prohibited abortions after the detection of embryonic cardiac activity, which occurs around 6 weeks after a person’s last menstrual period. After that point, SB8 allows abortions only in physician-documented medical emergencies. Anyone suspected of violating...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...